Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Primary Peritoneal Endometrioid Adenocarcinoma”

54 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 54 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04034927
What this trial is testing

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Who this might be right for
Fallopian Tube Endometrioid TumorFallopian Tube High Grade Serous AdenocarcinomaMalignant Ovarian Endometrioid Tumor+11 more
National Cancer Institute (NCI) 61
Early research (Phase 1)Study completedNCT00006235
What this trial is testing

Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Early research (Phase 1)Study completedNCT00066651
What this trial is testing

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

Who this might be right for
Cervical CancerFallopian Tube CancerHead and Neck Cancer+5 more
National Cancer Institute (NCI)
Early research (Phase 1)Ended earlyNCT03924245
What this trial is testing

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Who this might be right for
Fallopian Tube CancerFallopian Tube CarcinosarcomaFallopian Tube Clear Cell Adenocarcinoma+10 more
Vanderbilt-Ingram Cancer Center 3
Testing effectiveness (Phase 2)Study completedNCT00888615
What this trial is testing

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous Adenocarcinoma+15 more
GOG Foundation 58
Early research (Phase 1)Study completedNCT01074411
What this trial is testing

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous Adenocarcinoma+17 more
National Cancer Institute (NCI) 33
Large-scale testing (Phase 3)Active Not RecruitingNCT00565851
What this trial is testing

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Clear Cell AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+22 more
National Cancer Institute (NCI) 1,052
Early research (Phase 1)Study completedNCT01489371
What this trial is testing

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Who this might be right for
Ovarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous Carcinoma+5 more
Gynecologic Oncology Group 16
Testing effectiveness (Phase 2)Study completedNCT02283658
What this trial is testing

Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Who this might be right for
Ovarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous Cystadenocarcinoma+6 more
Mayo Clinic 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT01116648
What this trial is testing

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Who this might be right for
Fallopian Tube CarcinomaOvarian Endometrioid AdenocarcinomaOvarian High Grade Serous Adenocarcinoma+4 more
National Cancer Institute (NCI) 155
Not applicableEnded earlyNCT00904514
What this trial is testing

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 241
Large-scale testing (Phase 3)Study completedNCT00003322
What this trial is testing

Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group 384
Very early researchStudy completedNCT02111941
What this trial is testing

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Who this might be right for
Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid TumorFallopian Tube Mucinous Neoplasm+20 more
Mayo Clinic 19
Early research (Phase 1)Study completedNCT00006981
What this trial is testing

Immunotoxin Therapy in Treating Patients With Advanced Cancer

Who this might be right for
Cervical CancerFallopian Tube CancerHead and Neck Cancer+5 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT05231122
What this trial is testing

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Who this might be right for
Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous Adenocarcinoma+12 more
Roswell Park Cancer Institute 80
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07504588
What this trial is testing

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Who this might be right for
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid AdenocarcinomaRecurrent Platinum-Sensitive Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma+3 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT02923739
What this trial is testing

Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+17 more
M.D. Anderson Cancer Center 9
Early research (Phase 1)Ended earlyNCT00003380
What this trial is testing

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Study completedNCT02122185
What this trial is testing

Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Brenner TumorMalignant AscitesMalignant Pleural Effusion+25 more
University of Chicago 111
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Load More Results
87